Vanguard Personalized Indexing Management LLC Increases Stake in The Cooper Companies, Inc. (NASDAQ:COO)

Vanguard Personalized Indexing Management LLC boosted its holdings in shares of The Cooper Companies, Inc. (NASDAQ:COO) by 13.3% in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 19,500 shares of the medical device company’s stock after buying an additional 2,290 shares during the quarter. Vanguard Personalized Indexing Management LLC’s holdings in Cooper Companies were worth $1,688,000 at the end of the most recent reporting period.

A number of other institutional investors also recently bought and sold shares of COO. Vanguard Group Inc. raised its position in Cooper Companies by 303.0% during the 1st quarter. Vanguard Group Inc. now owns 23,099,975 shares of the medical device company’s stock worth $2,343,723,000 after buying an additional 17,367,502 shares during the last quarter. Capital World Investors raised its position in Cooper Companies by 301.7% during the 1st quarter. Capital World Investors now owns 5,654,023 shares of the medical device company’s stock worth $573,657,000 after buying an additional 4,246,519 shares during the last quarter. Janus Henderson Group PLC raised its position in Cooper Companies by 279.8% during the 1st quarter. Janus Henderson Group PLC now owns 3,437,064 shares of the medical device company’s stock worth $348,723,000 after buying an additional 2,532,186 shares during the last quarter. Bessemer Group Inc. raised its position in Cooper Companies by 305.2% during the 1st quarter. Bessemer Group Inc. now owns 2,000,910 shares of the medical device company’s stock worth $203,013,000 after buying an additional 1,507,049 shares during the last quarter. Finally, Swedbank AB purchased a new position in Cooper Companies during the 1st quarter worth approximately $139,246,000. 24.39% of the stock is owned by hedge funds and other institutional investors.

Insider Buying and Selling at Cooper Companies

In other Cooper Companies news, CAO Agostino Ricupati sold 1,601 shares of the firm’s stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $108.03, for a total value of $172,956.03. Following the transaction, the chief accounting officer now owns 4,818 shares in the company, valued at approximately $520,488.54. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. In other news, CAO Agostino Ricupati sold 1,601 shares of Cooper Companies stock in a transaction on Tuesday, September 10th. The stock was sold at an average price of $108.03, for a total transaction of $172,956.03. Following the transaction, the chief accounting officer now owns 4,818 shares in the company, valued at approximately $520,488.54. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. Also, COO Daniel G. Mcbride sold 114,992 shares of Cooper Companies stock in a transaction on Wednesday, September 4th. The stock was sold at an average price of $105.48, for a total value of $12,129,356.16. Following the transaction, the chief operating officer now owns 44,696 shares in the company, valued at approximately $4,714,534.08. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 256,373 shares of company stock worth $27,637,427. Corporate insiders own 2.00% of the company’s stock.

Cooper Companies Price Performance

Cooper Companies stock opened at $110.49 on Friday. The company’s fifty day moving average price is $97.93 and its 200 day moving average price is $95.50. The company has a debt-to-equity ratio of 0.33, a quick ratio of 1.18 and a current ratio of 1.99. The stock has a market capitalization of $22.00 billion, a P/E ratio of 64.99, a P/E/G ratio of 2.60 and a beta of 0.98. The Cooper Companies, Inc. has a 1 year low of $75.93 and a 1 year high of $112.38.

Cooper Companies (NASDAQ:COO) last announced its quarterly earnings data on Wednesday, August 28th. The medical device company reported $0.96 earnings per share for the quarter, beating analysts’ consensus estimates of $0.91 by $0.05. The company had revenue of $1 billion for the quarter, compared to analyst estimates of $997.30 million. Cooper Companies had a return on equity of 9.08% and a net margin of 9.45%. The firm’s revenue for the quarter was up 7.8% on a year-over-year basis. During the same quarter last year, the firm posted $0.84 EPS. As a group, equities research analysts anticipate that The Cooper Companies, Inc. will post 3.66 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts have issued reports on the stock. Wells Fargo & Company raised their price target on shares of Cooper Companies from $110.00 to $115.00 and gave the stock an “overweight” rating in a research report on Thursday, August 29th. Morgan Stanley raised their price objective on shares of Cooper Companies from $95.00 to $104.00 and gave the stock an “equal weight” rating in a research note on Tuesday, September 10th. Piper Sandler raised their price objective on shares of Cooper Companies from $115.00 to $120.00 and gave the stock an “overweight” rating in a research note on Thursday, August 29th. Robert W. Baird raised their price objective on shares of Cooper Companies from $118.00 to $125.00 and gave the stock an “outperform” rating in a research note on Thursday, August 29th. Finally, Stifel Nicolaus reaffirmed a “buy” rating and set a $115.00 price objective (up previously from $110.00) on shares of Cooper Companies in a research note on Thursday, August 29th. Four investment analysts have rated the stock with a hold rating and ten have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $115.00.

Cooper Companies Company Profile

The Cooper Companies, Inc, together with its subsidiaries, develops, manufactures, and markets contact lens wearers. The company operates in two segments, CooperVision and CooperSurgical. The CooperVision segment provides spherical lense, including lenses that correct near and farsightedness; and toric and multifocal lenses comprising lenses correcting vision challenges, such as astigmatism, presbyopia, and myopia in the Americas, Europe, Middle East, Africa, and Asia Pacific.